彭布罗利珠单抗
肾细胞癌
佐剂
肿瘤科
医学
内科学
癌
免疫疗法
癌症
作者
Toni K. Choueiri,Piotr Tomczak,Se Hoon Park,Balaji Venugopal,Tom Ferguson,Stefan N. Symeonides,Jaroslav Hájek,Yen-Hwa Chang,Jae‐Lyun Lee,Naveed Sarwar,Naomi B. Haas,Howard Gurney,Piotr Sawrycki,Mauricio Mahave,Marine Gross‐Goupil,Tian Zhang,John M. Burke,Gurjyot K. Doshi,Bohuslav Melichar,Evgeniy Kopyltsov
标识
DOI：10.1056/nejmoa2312695
摘要
Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
张欢馨
zzzz
大力的灵雁
pluto
你嵙这个期刊没买
畔畔
贪玩的秋柔
Criminology34
GingerF
1111
HEAR
辛勤的傲芙
嘉心糖
科研狗
子车茗
干净的琦
pcr163
双持裤衩武器战
iNk
皖公网安备34019202002308
